FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

Morning Topics:

  • A Thread To Pull: Unraveling The Complexities Of Myeloid Malignancies
  • Acute Myeloid Leukemia: Reviewing Current Best Practice And Exploring Novel Paradigms Ahead
  • Application Of The Latest Data In CLL/SLL: Guidance For Current And Future Treatment Strategies
  • Demystifying Cold Agglutinin Disease: A Visual Exploration Of Mechanism, Diagnosis, And The Role Of Complement Inhibition In Addressing Unmet Needs
  • Fixing The Target On Aggressive Lymphoma: Insights On The Next Phase Of Integrating Targeted Agents Into Mcl And Dlbcl Management
  • Maintaining ‘Intensity’ For Better Outcomes In Aml: Guidance On Modern, Intensive Upfront Platforms In Challenging Patient Populations
  • Myelodysplastic Syndromes 2022: Today And Tomorrow
  • Navigating The Frontier Of Hematologic Malignancy Therapies
  • Putting The Car(T) Before The Horse: Practicalities Of T Cell–Activating Therapies In Multiple Myeloma
  • Real-World, Real Innovation In Dlbcl: Perspectives On Integrating Novel Antibody Platforms Into Patient Care
  • The Rising Tide Of Car-T In Lymphoma: Guidance On Leveraging Cellular Therapy To Improve Outcomes Across The Spectrum Of Care
  • The Road To Remission In Multiple Myeloma: Expert Guidance On Using Bcma-Targeted Options To Enhance Clinical Outcomes
  • The Sequel To The Targeted Therapy Era In Cml: Guidance On Sequential Care And Integrating Established And Novel Options Into Cohesive Management Plans
  • The Winning Way With Btk Inhibitors In CLL: Evidence-Informed Choices On Treatment Selection, Safety, And Therapeutic Sequencing

Early Afternoon Topics:

  • A Conversation With The Myeloma Experts: Making Sense Of The Evolving Treatment Landscape
  • Acute Lymphoblastic Leukemia Data And Case Discussion On The Use Of Asparaginase Therapy In Young And Older Adults
  • Addressing Current Questions And Controversies In The Management Of Chronic Lymphocytic Leukemia – What Clinicians Want To Know (Part 1 Of A 3-Part CME-Accredited Symposia Series)
  • Advances In The Treatment Of T-Cell Lymphomas: A Forum For Data And Case Discussion
  • Amplifying The Role Of Accurate Diagnosis And New Therapeutic Options In The Treatment Of Hemolytic Anemias
  • An Expert Discussion On Myelodysplastic Syndromes: Current And Future Personalized Management Approaches
  • Bridging Clinical Gaps In Indolent And Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
  • Complement Clinical Cases: Navigating Care For Patients With Ahus, PNH, And HSCT-TMA
  • Elevating Equity In Caring For Patients With Hematologic Malignancies
  • Expert Illustrations And Commentaries™: Visualizing New Treatment Pathways For Anemia In Chronic Kidney Disease
  • Exploiting BCMA In The Treatment Of Multiple Myeloma: How Could Bispecific Antibodies And T-Cell Engagement Impact Relapsed/ Refractory Disease?
  • Fine-Tuning The Wave Of Innovation In CLL: Personalized Models For Upfront And Sequential Care With Groundbreaking Treatment
  • How We Do It™: Application Of State-Of-The-Art MF And PV Care Today… With An Eye Toward How New Evidence And Combinations Will Be Leveraged Tomorrow
  • Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions From Adolescent To Adult
  • MRD Assessment As A Cornerstone To Clinical Decision-Making In Hematologic Malignancies: Techniques, Utilization, And Best Practices To Optimize Patient Outcomes
  • Navigating A Changing Landscape Together: Gene Therapy For Hemophilia
  • Practice-Changing Data In Relapsed/Refractory Diffuse Large B-Cell Lymphoma—Integrating New Treatments
  • Rapidly Evolving Paradigms In Multiple Myeloma: Applying Current Data In The Clinic
  • State-Of-The-Art CMV Care: Experts’ Perspectives On Primary/Secondary Prevention And Management Of Refractory/Resistant Infections
  • Taking Stock Of The Evolving Treatment Landscape For Acute GVHD In HSCT
  • Transforming How We Treat Sickle Cell Disease: Holistic Approaches To Addressing Clinical Challenges Across The Patient’s Lifespan
  • Understanding The Biology And Addressing The Management Challenges Of Cytopenic Myelofibrosis

For the full list of symposia topics click here.